Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.
The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.
Daniel Cantillon, MD, explained why the positive performance of Abbott's Aveir dual-chamber leadless pacemaker could lead to considerable improvements in patient care.
Results from a pivotal clinical trial presented as a late-breaker at Heart Rhythm 2023 indicate that a new leadless pacemaker technology can deliver cardiac resynchronization therapy in patients who were not able to be treated with conventional CRT and epicardial leads.
The use of left bundle branch area pacing (LBBAP) is growing in electrophysiology implanted devices. Two late-breaking studies at Heart Rhythm 2023 highlight the success of LBBAP as an alternative to the standard of care using biventricular pacing.
The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.
“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
